Commerce Bank Takes Position in United Therapeutics Corporation $UTHR

Commerce Bank purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,447 shares of the biotechnology company’s stock, valued at approximately $784,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Northwestern Mutual Wealth Management Co. acquired a new stake in United Therapeutics in the 2nd quarter valued at about $341,000. Evolve Private Wealth LLC acquired a new position in United Therapeutics during the second quarter worth about $6,900,000. Emerald Investment Advisers LLC purchased a new stake in shares of United Therapeutics in the second quarter valued at about $5,025,000. Korea Investment CORP purchased a new stake in shares of United Therapeutics in the second quarter valued at about $9,645,000. Finally, EP Wealth Advisors LLC acquired a new stake in shares of United Therapeutics in the second quarter valued at approximately $566,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently weighed in on UTHR. Royal Bank Of Canada dropped their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. JPMorgan Chase & Co. upped their target price on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Morgan Stanley set a $515.00 price target on United Therapeutics in a research report on Thursday, August 6th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $646.00.

United Therapeutics Trading Down 0.4%

NASDAQ:UTHR opened at $516.68 on Thursday. United Therapeutics Corporation has a 12-month low of $302.19 and a 12-month high of $609.35. The firm has a market cap of $22.16 billion, a price-to-earnings ratio of 18.49, a price-to-earnings-growth ratio of 1.76 and a beta of 0.59. The company’s 50-day moving average is $531.06 and its two-hundred day moving average is $538.56.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.41 earnings per share. On average, equities research analysts forecast that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $547.61, for a total transaction of $5,202,295.00. Following the sale, the chief executive officer owned 40,513 shares in the company, valued at approximately $22,185,323.93. This trade represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $546.28, for a total transaction of $5,462,800.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,311,581.28. The trade was a 34.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 424,075 shares of company stock worth $227,683,710 in the last three months. Insiders own 8.60% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.